ES2946632T7 - Moduladores de AhR - Google Patents

Moduladores de AhR Download PDF

Info

Publication number
ES2946632T7
ES2946632T7 ES19706135T ES19706135T ES2946632T7 ES 2946632 T7 ES2946632 T7 ES 2946632T7 ES 19706135 T ES19706135 T ES 19706135T ES 19706135 T ES19706135 T ES 19706135T ES 2946632 T7 ES2946632 T7 ES 2946632T7
Authority
ES
Spain
Prior art keywords
methyl
trifluoromethyl
phenyl
quinazolin
pyrazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19706135T
Other languages
English (en)
Spanish (es)
Other versions
ES2946632T3 (es
Inventor
Muzaffar Alam
Hilary Beck
Michael Dillon
Marcos Gonzalez-Lopez
James Sutton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ideaya Biosciences Inc
Original Assignee
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc filed Critical Ideaya Biosciences Inc
Application granted granted Critical
Publication of ES2946632T3 publication Critical patent/ES2946632T3/es
Publication of ES2946632T7 publication Critical patent/ES2946632T7/es
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Supplying Of Containers To The Packaging Station (AREA)
ES19706135T 2018-02-06 2019-02-05 Moduladores de AhR Active ES2946632T7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862626739P 2018-02-06 2018-02-06
US201962793260P 2019-01-16 2019-01-16
PCT/US2019/016705 WO2019156987A1 (en) 2018-02-06 2019-02-05 AhR MODULATORS

Publications (2)

Publication Number Publication Date
ES2946632T3 ES2946632T3 (es) 2023-07-21
ES2946632T7 true ES2946632T7 (es) 2025-03-04

Family

ID=65494575

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19706135T Active ES2946632T7 (es) 2018-02-06 2019-02-05 Moduladores de AhR

Country Status (10)

Country Link
US (3) US10815250B2 (cg-RX-API-DMAC7.html)
EP (2) EP4219495A1 (cg-RX-API-DMAC7.html)
JP (1) JP7382348B2 (cg-RX-API-DMAC7.html)
CN (1) CN111683950B (cg-RX-API-DMAC7.html)
CA (1) CA3090150A1 (cg-RX-API-DMAC7.html)
DK (1) DK3749669T6 (cg-RX-API-DMAC7.html)
ES (1) ES2946632T7 (cg-RX-API-DMAC7.html)
FI (1) FI3749669T6 (cg-RX-API-DMAC7.html)
TW (1) TWI840343B (cg-RX-API-DMAC7.html)
WO (1) WO2019156987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018562A1 (en) * 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP4219495A1 (en) 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Ahr modulators
KR20260057216A (ko) * 2019-11-22 2026-04-27 세일 바이오메디슨스, 인크. Ahr 길항제로서의 피리도피리미디논 유도체
MX2022012739A (es) * 2020-04-17 2022-11-07 Dong A St Co Ltd Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022081649A1 (en) * 2020-10-13 2022-04-21 Senda Biosciences, Inc. Biomarkers related to immune checkpoint inhibitor therapy and methods of using the same
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN118076613A (zh) * 2021-09-02 2024-05-24 捷豹治疗有限公司 可用于调节AhR信号传导的化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
CA2454080A1 (en) 2001-08-13 2003-02-27 Robert Edward Detlefsen Ultraviolet light absorbers
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CA2700988A1 (en) 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
UA106037C2 (uk) 2008-02-04 2014-07-25 Мерк'Юрі Терап'Ютікс, Інк. Модулятори ampk (амф-активованої протеїнкінази)
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
CN102105464A (zh) 2008-05-27 2011-06-22 德克萨斯大学系统董事会 Wnt蛋白信号转导抑制剂
MX2011009568A (es) 2009-03-09 2011-12-06 Surface Logix Inc Inhibidores de la rho cinasa.
WO2010148350A1 (en) * 2009-06-18 2010-12-23 Cornell University Photoproducts of tryptophan, their synthesis and uses thereof
US10314810B2 (en) * 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
KR20130065728A (ko) * 2010-10-14 2013-06-19 임뮤나르 에이비 Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US11427600B2 (en) * 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
WO2017184547A1 (en) 2016-04-18 2017-10-26 New York University Quinoline compounds as modulators of rage activity and uses thereof
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP4219495A1 (en) 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Ahr modulators
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds

Also Published As

Publication number Publication date
CN111683950A (zh) 2020-09-18
EP4219495A1 (en) 2023-08-02
TWI840343B (zh) 2024-05-01
EP3749669A1 (en) 2020-12-16
FI3749669T6 (fi) 2024-11-13
US12258354B2 (en) 2025-03-25
JP2021512954A (ja) 2021-05-20
US20190270754A1 (en) 2019-09-05
JP7382348B2 (ja) 2023-11-16
US11407764B2 (en) 2022-08-09
US20210002297A1 (en) 2021-01-07
CA3090150A1 (en) 2019-08-15
US20230039955A1 (en) 2023-02-09
US10815250B2 (en) 2020-10-27
FI3749669T3 (fi) 2023-05-26
TW201945362A (zh) 2019-12-01
WO2019156987A1 (en) 2019-08-15
ES2946632T3 (es) 2023-07-21
DK3749669T6 (da) 2024-11-18
EP3749669B1 (en) 2023-03-08
EP3749669B3 (en) 2024-09-04
DK3749669T3 (da) 2023-06-06
CN111683950B (zh) 2024-04-16

Similar Documents

Publication Publication Date Title
ES2946632T3 (es) Moduladores de AHR
AU2021390194B2 (en) Substituted thiadiazolyl derivatives as dna polymerase theta inhibitors
CN112166110B (zh) Shp2磷酸酶抑制剂及其使用方法
ES2982474T3 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
ES2805087T3 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la cinasa RET
JP6133291B2 (ja) ピラゾロ[3,4−c]ピリジン化合物と使用方法
ES2738329T3 (es) Compuestos de heteroarilpiridona y aza-piridona como inhibidores de la actividad btk
RU2617405C2 (ru) Пиридоновые и азапиридоновые соединения и способы применения
KR20220100879A (ko) Fgfr 저해제로서의 이환식 헤테로사이클
TWI878423B (zh) 環狀化合物及其使用方法
AU2017206061A1 (en) Modulators of 5'-nucleotidase, ecto and the use thereof
US12319671B2 (en) 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
US11530220B2 (en) Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR
JP2022525199A (ja) Eedおよびprc2調節物質としての大環状アゾロピリジン誘導体
JP2025525364A (ja) Axlの阻害剤としての化合物
EP4284804A1 (en) Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
WO2019067442A1 (en) DIHYDROTHIENO [3,2-B] PYRIDINE COMPOUNDS
ES3034384T3 (en) Cyclic compounds and methods of using same
CN117120442A (zh) 用于治疗癌症、自身免疫性病症和炎性病症的三环化合物
HK40042159B (en) Ahr modulators
EP4705292A1 (en) Cbl-b inhibitors and methods of use thereof
CN121159575A (zh) 氨基取代的杂芳环类化合物、其制备方法及其在医药上的应用